Modifying provider behavior: A low-tech approach to pharmaceutical ordering

Journal of General Internal Medicine

Volumn 17, Issue 10, 2002, Pages 792-796

  Guterman, Jeffrey J ^a,b,d   Chernof, Bruce A ^a,b,c   Mares, Beatriz ^a   Gross Schulman, Sandra G ^c,d   Gan, Pramod G ^a,b,d   Thomas, Donald ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OLIVE VIEW UCLA MEDICAL CENTER   (United States)

^c Foundation Health Systems   (United States)

^d LOS ANGELES COUNTY DEPARTMENT OF HEALTH SERVICES   (United States)

Author keywords

Pharmaceutical cost; Provider behavior modification; Structured prescription forms

Indexed keywords

CIMETIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; RANITIDINE;

ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG PREFERENCE; HUMAN; MEDICAL PRACTICE; PATIENT CARE; PHARMACEUTICAL CARE; PHYSICIAN ATTITUDE; PRESCRIPTION; TREATMENT INDICATION;

ATTITUDE OF HEALTH PERSONNEL; DRUG COSTS; DRUG UTILIZATION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, FAMILY; PRESCRIPTIONS, DRUG;

EID: 0036406887     PISSN: 08848734     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1497.2002.20144.x     Document Type: Article

References (17)

1. Levit KR, Lazenby HC, Braden BR, and the National Health Accounts Team. National health spending trends in 1996. Health Aft. 1998;17:35-51.
2. Iglehart JK. The American health care system: Expenditures. N Engl J Med. 1999;340:70-6.
3. Hux JE, Melady MP, DeBoer D. Confidential prescriber feedback and education to improve antibiotic use in primary care: A controlled trial. CMAJ. 1999;161:388-92.
4. Kong KM, Johnson WF, Anderson PO, Sato LA, Simonian RI. Effect of a pharmacy-based cost-containment program on cimetidine costs and use. Am J Hosp Pharm. 1987;44:2068-73.
5. Algozzine GJ, Sprenger RL, Caselnova DA, Proper P. Pharmacy intern intervention to reduce costs associated with histamine H2-antagonist therapy. Am J Hosp Pharm. 1989;46:1183-84.
6. Briceland LL, Lesar TS, Lomaestro BM, Lombardi TP, Gailey RA, Kowalsky SF. Streamlining antimicrobial therapy through pharmacists' review of order sheets. Am J Hosp Pharm. 1989;46:1376-80.
7. Raisch DW, Bootman JL, Larson LN, McGhan WF. Improving antiulcer agent prescribing in a health maintenance organization. Am J Hosp Pharm. 1990;47:1766-73.
8. Falbe WJ, Bess DT, Capers CC, Haymond JD, Stahl AA. Effect of a criteria-based cost-containment program on the selection of oral H2-receptor antagonists. Am J Hosp Pharm. 1992;49:632-3.
9. Brufsky JW, Ross-Degnan D, Calabrese D, Gao X, Soumerai SB. Shifting physician prescribing to a preferred histamine-2-receptor antagonist. Effects of a multffactorial intervention in a mixed-model health maintenance organization. Med Care. 1998;36:321-32.
10. Hasty M, Schrager J, Wrenin K. Physicians' perceptions about managed care restrictions on antibiotic prescribing. J Gen Intern Med. 1999;14:756-8.
11. Sbarbaro JA. Can we influence prescribing patterns? Clin Infect Dis. 2001;33“Suppl 3”:240-4.
12. Evans RS, Classen DC, Pestotnik SL, Clemmer TP, Weaver LK, Burke JP. A decision support tool for antibiotic therapy. In: Proc Annu Symp Comput Appl Med Care. 1995;651-5.
13. Shojania KG, Yokoe D, Platt R, Fiskio J, Ma'luf N, Bates D. Reducing vancomycin use utilizing a computer guideline: Results of a randomized controlled trial. J Am Med Inform Assoc. 1998;5:554-62.
14. Rawlings RD. Therapeutic exchange of cefotaxime for ceftriaxone: Evaluation, implementation, and subsequent cost savings at a 300-bed community hospital. Diagn Microbiol Infect Dis. 1995;22:235-37.
15. Chase SL, Peterson AM, Wordell CJ. Therapeutic-interchange program for oral histamine H2-receptor antagonists. Am J Health Syst Pharm. 1998;55:1382-6.
16. Roth EJ, Plastaras CT, Mullin MS, Fillmore J, Moses ML. A simple institutional intervention to decrease use of selected expensive medications. Arch Phys Med Rehabil. 2001;82:633-6.
17. California Code of Regulations. Title 16, Division 17, Section 1717.3.